Tyrosine kinase inhibitors in acute and chronic leukemias

摘要: Introduction: Since the initial approval of imatinib much has been learned about its resistance mechanisms, and efforts have continued to improve upon BCR-ABL tyrosine kinase inhibitor therapy. Targeted therapy with TKIs be an area active research development in care acute chronic leukemia patients. Areas covered: This article reviews current approved investigational TKI treatments for myelogenous (CML), Philadelphia-chromosome positive lymphoblastic (Ph + ALL) (AML). Expert opinion: There are now more potent approved, which allow additional options when determining front-line second-line CML Ph ALL treatments. The T315I mutation is ever-present challenge. Ponatinib, a pan TKI, while still under investigation, very hopeful ability overcome mutations resistant Because nilotinib dasatinib not directly comp...